These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 33619320)

  • 1. Gut microbiome diversity is an independent predictor of survival in cervical cancer patients receiving chemoradiation.
    Sims TT; El Alam MB; Karpinets TV; Dorta-Estremera S; Hegde VL; Nookala S; Yoshida-Court K; Wu X; Biegert GWG; Delgado Medrano AY; Solley T; Ahmed-Kaddar M; Chapman BV; Sastry KJ; Mezzari MP; Petrosino JF; Lin LL; Ramondetta L; Jhingran A; Schmeler KM; Ajami NJ; Wargo J; Colbert LE; Klopp AH
    Commun Biol; 2021 Feb; 4(1):237. PubMed ID: 33619320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microbial Diversity and Composition Is Associated with Patient-Reported Toxicity during Chemoradiation Therapy for Cervical Cancer.
    Mitra A; Grossman Biegert GW; Delgado AY; Karpinets TV; Solley TN; Mezzari MP; Yoshida-Court K; Petrosino JF; Mikkelson MD; Lin L; Eifel P; Zhang J; Ramondetta LM; Jhingran A; Sims TT; Schmeler K; Okhuysen P; Colbert LE; Klopp AH
    Int J Radiat Oncol Biol Phys; 2020 May; 107(1):163-171. PubMed ID: 31987960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics of Intratumoral Immune Cell Activation During Chemoradiation for Cervical Cancer.
    Dorta-Estremera S; Colbert LE; Nookala SS; Yanamandra AV; Yang G; Delgado A; Mikkelson M; Eifel P; Jhingran A; Lilie LL; Welsh J; Schmeler K; Sastry JK; Klopp A
    Int J Radiat Oncol Biol Phys; 2018 Nov; 102(3):593-600. PubMed ID: 30017792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Dynamic Alternation of Local and Systemic Tumor Immune Microenvironment During Concurrent Chemoradiotherapy of Cervical Cancer: A Prospective Clinical Trial.
    Li R; Liu Y; Yin R; Yin L; Li K; Sun C; Zhou Z; Li P; Tong R; Xue J; Lu Y
    Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1432-1441. PubMed ID: 33713744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4
    Piersiala K; Farrajota Neves da Silva P; Hjalmarsson E; Kolev A; Kågedal Å; Starkhammar M; Elliot A; Marklund L; Margolin G; Munck-Wikland E; Kumlien Georén S; Cardell LO
    Cancer Sci; 2021 Mar; 112(3):1048-1059. PubMed ID: 33462898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls.
    Sims TT; Colbert LE; Zheng J; Delgado Medrano AY; Hoffman KL; Ramondetta L; Jazaeri A; Jhingran A; Schmeler KM; Daniel CR; Klopp A
    Gynecol Oncol; 2019 Nov; 155(2):237-244. PubMed ID: 31500892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B7-H4 overexpression impairs the immune response of T cells in human cervical carcinomas.
    Wang X; Wang T; Xu M; Xiao L; Luo Y; Huang W; Zhang Y; Geng W
    Hum Immunol; 2014 Dec; 75(12):1203-9. PubMed ID: 25446402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunologic impact of chemoradiation in cervical cancer and how immune cell infiltration could lead toward personalized treatment.
    Lippens L; Van Bockstal M; De Jaeghere EA; Tummers P; Makar A; De Geyter S; Van de Vijver K; Hendrix A; Vandecasteele K; Denys H
    Int J Cancer; 2020 Jul; 147(2):554-564. PubMed ID: 32017078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic cancer alters human CD4+ T lymphocyte function: a piece in the immune evasion puzzle.
    Fogar P; Basso D; Fadi E; Greco E; Pantano G; Padoan A; Bozzato D; Facco M; Sanzari MC; Teolato S; Zambon CF; Navaglia F; Semenzato G; Pedrazzoli S; Plebani M
    Pancreas; 2011 Oct; 40(7):1131-7. PubMed ID: 21792088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cervical cancer patients that respond to chemoradiation therapy display an intense tumor infiltrating immune profile before treatment.
    Martins PR; Machado CMT; Coxir SA; de Oliveira AJ; Moreira TB; Campos LS; Alcântara R; de Paula SOC; de Oliveira Salles PG; Gollob KJ; Magalhães WCS
    Exp Mol Pathol; 2019 Dec; 111():104314. PubMed ID: 31654628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC.
    Jin Y; Dong H; Xia L; Yang Y; Zhu Y; Shen Y; Zheng H; Yao C; Wang Y; Lu S
    J Thorac Oncol; 2019 Aug; 14(8):1378-1389. PubMed ID: 31026576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of chemoradiation on the immune microenvironment of cervical cancer patients.
    Herter JM; Kiljan M; Kunze S; Reinscheid M; Ibruli O; Cai J; Niu L; Heßelmann I; Trommer M; Herter-Sprie GS; Köhler C; Marnitz S
    Strahlenther Onkol; 2023 Feb; 199(2):121-130. PubMed ID: 36251031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ki67 expression and localization of T cells after neoadjuvant therapies as reliable predictive markers in rectal cancer.
    Imaizumi K; Suzuki T; Kojima M; Shimomura M; Sakuyama N; Tsukada Y; Sasaki T; Nishizawa Y; Taketomi A; Ito M; Nakatsura T
    Cancer Sci; 2020 Jan; 111(1):23-35. PubMed ID: 31660687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumour microbiome associated with the infiltration of cytotoxic CD8+ T cells and patient survival in cutaneous melanoma.
    Zhu G; Su H; Johnson CH; Khan SA; Kluger H; Lu L
    Eur J Cancer; 2021 Jul; 151():25-34. PubMed ID: 33962358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
    Santin AD; Ravaggi A; Bellone S; Pecorelli S; Cannon M; Parham GP; Hermonat PL
    Gynecol Oncol; 2001 Jun; 81(3):424-32. PubMed ID: 11371133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic roles for IL-2-producing and CD69
    Taylor ES; McCall JL; Shen S; Girardin A; Munro FM; Black MA; Ward-Hartstonge KA; Kemp RA
    Int J Cancer; 2018 Oct; 143(8):2008-2016. PubMed ID: 29752720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of tumor cells in the modification of T lymphocytes activity--the expression of the early CD69+, CD71+ and the late CD25+, CD26+, HLA/DR+ activation markers on T CD4+ and CD8+ cells in squamous cell laryngeal carcinoma. Part I.
    Starska K; Głowacka E; Kulig A; Lewy-Trenda I; Bryś M; Lewkowicz P
    Folia Histochem Cytobiol; 2011; 49(4):579-92. PubMed ID: 22252752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD69 regulates type I IFN-induced tolerogenic signals to mucosal CD4 T cells that attenuate their colitogenic potential.
    Radulovic K; Manta C; Rossini V; Holzmann K; Kestler HA; Wegenka UM; Nakayama T; Niess JH
    J Immunol; 2012 Feb; 188(4):2001-13. PubMed ID: 22250092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human hepatocellular carcinoma-infiltrating CD4⁺CD69⁺Foxp3⁻ regulatory T cell suppresses T cell response via membrane-bound TGF-β1.
    Han Y; Yang Y; Chen Z; Jiang Z; Gu Y; Liu Y; Xu S; Lin C; Pan Z; Zhou W; Cao X
    J Mol Med (Berl); 2014 May; 92(5):539-50. PubMed ID: 24668348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of the immunological phenomena and relationship with clinicopathological characteristics of the tumor--the expression of the early CD69+, CD71+ and the late CD25+, CD26+, HLA/DR+ activation markers on T CD4+ and CD8+ lymphocytes in squamous cell laryngeal carcinoma. Part II.
    Starska K; Głowacka E; Kulig A; Lewy-Trenda I; Bryś M; Lewkowicz P
    Folia Histochem Cytobiol; 2011; 49(4):593-603. PubMed ID: 22252753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.